Q-omics provides the consensus-scored MIR6817 profile across patient tissues and cancer cell-line models. MIR6817 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR6817 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR6817 RNA expression shows 3,820 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight ESCA, THCA, and KIRC as cancer lineages where MIR6817 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6817 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6817 survival associations across molecular data types. MIR6817 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6817 RNA expression–survival associations across cancer types. High MIR6817 expression shows unfavorable associations in ESCA, OV, ACC, CHOL, UCEC and BLCA. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR6817 RNA expression.
This table summarizes MIR6817 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6817. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6817 shows lower tumor expression in THCA. The THCA box plot shows higher MIR6817 RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .042).
This table shows molecular features associated with MIR6817 in patient tissues and cancer cell lines. In patient samples, MIR6817 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
